Evidence map›Paper›PMID 40994822›Full record

ArticleBrain communications2025

Effect of leukotriene receptor antagonist use on the future risk of Parkinson's disease in older patients with asthma.

Chengsheng Ju, Boqing Chen, Anette Schrag, Camille Carroll, Thomas Foltynie, Li Wei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chengsheng JuResearch Department of Practice and Policy, University College London School of Pharmacy, London WC1N 1AX, United Kingdom.ORCID https://orcid.org/0000-0001-7860-6262
Boqing ChenResearch Department of Practice and Policy, University College London School of Pharmacy, London WC1N 1AX, United Kingdom.
Anette SchragDepartment of Clinical and Movement Neurosciences, University College London Institute of Neurology, London WC1N 3BG, United Kingdom.
Camille CarrollTranslational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, NE1 7RU, United Kingdom.
Thomas FoltynieDepartment of Clinical and Movement Neurosciences, University College London Institute of Neurology, London WC1N 3BG, United Kingdom.ORCID https://orcid.org/0000-0003-0752-1813
Li WeiResearch Department of Practice and Policy, University College London School of Pharmacy, London WC1N 1AX, United Kingdom.ORCID https://orcid.org/0000-0001-8840-7267

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current treatments for Parkinson's disease focus on symptom management, with no therapies yet demonstrated to slow disease progression. Leukotriene receptor antagonists, widely used for asthma, have shown potential neuroprotective effects for Parkinson's disease in preclinical studies, but have also been associated with an elevated risk of neuropsychiatric events and sleep disorders. We assessed the effect of leukotriene receptor antagonist treatment on the risk of Parkinson's disease, neuropsychiatric events, and sleep disorders in patients with asthma aged over 50 years. We conducted a cohort study using the UK Clinical Practice Research Datalink between January 2000 and December 2020. The study emulated sequential target trials (

Indexed as

asthmaleukotriene receptor antagonistParkinson’s diseasetarget trial emulation

Identifiers

PMID40994822
PMCPMC12455039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.